Modern Aspects of Cutaneous Neurogenic Inflammation

Archives of Dermatology

Volumn 139, Issue 11, 2003, Pages 1479-1488

  Steinhoff, Martin ^a   Ständer, Sonja ^a   Seeliger, Stephan ^a   Ansel, John C ^c   Schmelz, Martin ^b   Luger, Thomas ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c EAST WEST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADRENALIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; CATHEPSIN G; DIPEPTIDYL CARBOXYPEPTIDASE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MEMBRANE METALLOENDOPEPTIDASE; NEUROHORMONE; NEUROPEPTIDE; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; NEUROTROPHIN; NEUROTROPHIN 3; NEUROTROPHIN 4; NORADRENALIN; PROOPIOMELANOCORTIN; TACHYKININ; THROMBIN; TRYPSIN; TRYPTASE; VANILLOID RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

ATOPIC DERMATITIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATION; ENDOCRINE SYSTEM; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; KERATINOCYTE; LANGERHANS CELL; LEUKOCYTE; MAST CELL; NERVE TRACT; NEUROBIOLOGY; NEUROLOGIC DISEASE; PERIPHERAL NERVE; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN SECRETION; PRURITUS; PSORIASIS; REVIEW; ROSACEA; SKIN CELL; SKIN INFLAMMATION; SKIN NERVE; TARGET CELL; URTICARIA; VASODILATATION; WOUND HEALING;

DERMATITIS; HUMANS; NEUROGENIC INFLAMMATION; NEUROPEPTIDES; PERIPHERAL NERVES;

EID: 0242408748     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.11.1479     Document Type: Review

References (183)

1. Brain SD, Williams TJ. Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br J Pharmacol. 1985;86:855-860.
2. Wallengren J, Badendick K, Sundler F, Hakanson R, Zander E. Innervation of the skin of the forearm in diabetic patients. Acta Derm Venereol. 1995;75:37-42.
3. Grando SA. Biological functions of keratinocyte cholinergic receptors. J Investig Dermatol Symp Proc. 1997;2:41-48.
4. Seiffert K, Hosoi J, Torii H, et al. Catecholamines inhibit the antigen-presenting capability of epidermal Langerhans cells. J Immunol. 2002;168: 6128-6135.
5. Paus R, Peters EM, Eichmuller S, Botchkarev VA. Neural mechanisms of hair growth control. J Investig Dermatol Symp Proc. 1997;2:61-68.
6. Schallreuter KU. Epidermal adrenergic signal transduction as part of the neuronal network in the human epidermis. J Investig Dermatol Symp Proc. 1997; 2:37-40.
7. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev. 2000; 21:457-487.
8. Seiffert K, Granstein RD. Neuropeptides and neuroendocrine hormones in ultraviolet radiation-induced immunosuppression. Methods. 2002;28:97-103.
9. Szolcsanyi J. Capsaicin-sensitive sensory nerve terminals with local and systemic efferent functions. Prog Brain Res. 1996;113:343-359.
10. Legat FJ, Armstrong CA, Ansel JC. The cutaneous neurosensory system in skin disease. Adv Dermatol. 2002;18:91-109.
11. Ansel JC, Armstrong CA, Song I, et al. Interactions of the skin and nervous system. J Investig Dermatol Symp Proc. 1997;2:23-26.
12. Slominski A, Wortsman J, Pisarchik A, et al. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J. 2001; 15:1678-1693.
13. Misery L. Langerhans cells in the neuro-immuno-cutaneous system. J Neuroimmunol. 1998;89:83-87.
14. Luger TA. Neuromediators: a crucial component of the skin immune system. J Dermatol Sci. 2002;30:87-93.
15. Steinhoff M, Ständer S, Luger TA. Regulatory mechanisms of neuroimmunology of the skin. In: Bienenstock J, Goetzl EJ, eds. Biology of the Autonomic Nervous System. New York, NY: Marcel Dekker Inc; 2002:279-298
16. Misery L. Skin, immunity and the nervous system. Br J Dermatol. 1997;137: 843-850.
17. Freidin M, Kessler JA. Cytokine regulation of substance P expression in sympathetic neurons. Proc Natl Acad Sci U S A. 1991;88:3200-3203.
18. Bost KL, Breeding SA, Pascual DW. Modulation of the mRNAs encoding substance P and its receptor in rat macrophages by LPS Reg Immunol. 1992;4: 105-112.
19. Furutani K, Koro O, Hide M, Yamamoto S. Substance P- and antigen-induced release of leukotriene B4, prostaglandin D2 and histamine from guinea pig skin by different mechanisms in vitro. Arch Dermatol Res. 1999;291:466-473
20. Theoharides TC, Singh LK, Boucher W, et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology. 1998;139:403-413.
21. Wiedermann CJ, Auer B, Sitte B, et al. Induction of endothelial cell differentiation into capillary-like structures by substance P. Eur J Pharmacol. 1996;298: 335-338.
22. Quinlan KL, Song IS, Naik SM, et al. VCAM-1 expression on human dermal microvascular endothelial cells is directly and specifically up-regulated by substance P. J Immunol. 1999;162:1656-1661.
23. Pinter E, Than M, Chu DQ, Fogg C, Brain SD. Interaction between interleukin 1β and endogenous neurokinin 1 receptor agonists in mediating plasma extravasation and neutrophil accumulation in the cutaneous microvasculature of the rat. Neurosci Lett. 2002;318:13-16.
24. McGovern UB, Jones KT, Sharpe GR. Intracellular calcium as a second messenger following growth stimulation of human keratinocytes. Br J Dermatol. 1995;132:892-896.
25. Song IS, Bunnett NW, Olerud JE, et al. Substance P induction of murine keratinocyte PAM 212 interleukin 1 production is mediated by the neurokinin 2 receptor (NK-2R). Exp Dermatol. 2000;9:42-52.
26. Viac J, Gueniche A, Doutremepuich JD, Reichert U, Claudy A, Schmitt D. Substance P and keratinocyte activation markers: an in vitro approach. Arch Dermatol Res. 1996;288:85-90.
27. Kahler CM, Sitte BA, Reinisch N, Wiedermann CJ. Stimulation of the chemotactic migration of human fibroblasts by substance P. Eur J Pharmacol. 1993; 249:281-286.
28. Katayama I, Nishioka K. Substance P augments fibrogenic cytokine-induced fibroblast proliferation J Dermatol Sci. 1997;15:201-206.
29. Quinlan KL, Naik SM, Cannon G, et al. Substance P activates coincident NF-AT-and NF-kappa B-dependent adhesion molecule gene expression in microvascular endothelial cells through intracellular calcium mobilization. J Immunol. 1999:163:5656-5665.
30. Staniek V, Misery L, Peguet-Navarro J, et al. Binding and in vitro modulation of human epidermal Langerhans cell functions by substance P. Arch Dermatol Res. 1997;289:285-291.
31. Cao T, Pinter E, Al-Rashed S, Gerard N, Hoult JR, Brain SD. Neurokinin-1 receptor agonists are involved in mediating neutrophil accumulation in the inflamed, but not normal, cutaneous microvasculature. J Immunol. 2000;164: 5424-5429.
32. Cao T, Grant AD, Gerard NP, Brain SD. Lack of a significant effect of deletion of the tachykinin neurokinin-1 receptor on wound healing in mouse skin. Neuroscience. 2001;108:695-700.
33. Palframan RT, Costa SK, Wilsoncroft P, Antunes E, de Nucci G, Brain SD. The effect of a tachykinin NK1 receptor antagonist, SR140333, on oedema formation induced in rat skin by venom from the Phoneutria nigriventer spider. Br J Pharmacol. 1996;118:295-298.
34. Habler HJ, Timmermann L, Stegmann JU, Janig W. Involvement of neurokinins in antidromic vasodilatation in hairy and hairless skin of the rat hindlimb. Neuroscience. 1999;89:1259-1268.
35. Lofgren O, Qi Y, Lundeberg T. Inhibitory effects of tachykinin receptor antagonists on thermally induced inflammatory reactions in a rat model. Burns. 1999; 25:125-129.
36. Harvima IT, Viinamaki H, Naukkarinen A, et al. Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. Psychother Psychosom. 1993;60:168-176.
37. Eedy DJ, Johnston CF, Shaw C, Buchanan KD. Neuropeptides in psoriasis. J Invest Dermatol. 1991;96:434-438.
38. Lundeberg L, Nordlind K. Vasoactive intestinal polypeptide in allergic contact dermatitis: an immunohistochemical and radioimmunoassay study. Arch Dermatol Res. 1999;291:201-206.
39. Lundeberg L, Mutt V, Nordlind K. Inhibitory effect of vasoactive intestinal peptide on the challenge phase of allergic contact dermatitis in humans. Acta Derm Venereol. 1999;79:178-182.
40. Bondesson L, Nordlind K, Mutt V, Liden S. Vasoactive intestinal polypeptide inhibits the established allergic contact dermatitis in humans. Ann N Y Acad Sci. 1996;805:702-707.
41. Williams TJ. Vasoactive intestinal polypeptide is more potent than prostaglandin E2 as a vasodilator and oedema potentiator in rabbit skin. Br J Pharmacol. 1982;77:505-509.
42. Wollina U, Huschenbeck J, Knoll B, Sternberg B, Hipler UC. Vasoactive intestinal peptide supports induced migration of human keratinocytes and their colonization of an artificial polyurethane matrix. Regul Pept. 1997;70:29-36.
43. Sato K, Sato F. Effect of VIP on sweat secretion and cAMP accumulation in isolated simian eccrine glands. Am J Physiol. 1987;253:R935-R941.
44. Warren JB, Wilson AJ, Loi RK, Coughlan ML. Opposing roles of cyclic AMP in the vascular control of edema formation. FASEB J. 1993;7:1394-1400.
45. Fischer TC, Dinh QT, Peiser C, Loser C, Fischer A, Groneberg DA. Simultaneous detection of receptor mRNA and ligand protein in human skin tissues. J Cutan Pathol. 2002;29:65-71.
46. Hosoya M, Onda H, Ogi K, et al. Molecular cloning and functional expression of rat cDNAs encoding the receptorfor pituitary adenylate cyclase activating polypeptide (PACAP). Biochem Biophys Res Commun. 1993;194:133-143.
47. Dun EC, Huang RL, Dun SL, Dun NJ. Pituitary adenylate cyclase activating polypeptide-immunoreactivity in human spinal cord and dorsal root ganglia, Brain Res. 1996;721:233-237.
48. Warren JB, Larkin SW, Coughlan M, Kajekar R, Williams TJ. Pituitary adenylate cyclase activating polypeptide is a potent vasodilator and oedema potentiator in rabbit skin in vivo. Br J Pharmacol. 1992;106:331-334.
49. Cardell LO, Stjarne P, Wagstaff SJ, Agusti C, Nadel JA. PACAP-induced plasma extravasation in rat skin. Regul Pept. 1997;71:67-71.
50. Schmidt-Choudhury A, Meissner J, Seebeck J, et al. Stem cell factor influences neuro-immune interactions. Regul Pept. 1999;83:73-80.
51. Odum L, Petersen LJ, Skov PS, Ebskov LB. Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm Res. 1998;47:488-492.
52. Steinhoff M, McGregor GP, Radleff-Schlimme A, Steinhoff A, Jarry H, Schmidt WE. Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin. Regul Pept. 1999;80:49-55.
53. Arimura A, Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors. Front Neuroendocrinol. 1995;16:53-88,
54. Granothab R, Fridkinb M, Gozesa I. VIP and the potent analog, stearyl-Nle(17)-VIP, induce proliferation of keratinocytes. FEBS Lett. 2000;475:78-83.
55. Sung KJ, Chang SE, Paik EM, Lee MW, Choi JH. Vasoactive intestinal polypeptide stimulates the proliferation of HaCaT cell via TGF-alpha. Neuropeptides. 1999; 33:435-446.
56. Martinez C, Delgado M, Pozo D, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol. 1998;63:591-601.
57. Delgado M, Pozo D, Martinez C. et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages. J Immunol. 1999;162:2358-2367.
58. Delgado M, Martinez C, Pozo D, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol. 1999;162:1200-1205.
59. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med. 2001;7:563-568.
60. Abad C, Martinez C, Leceta J, Gomariz RP, Delgado M. Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. J Immunol. 2001;167:3182-3189.
61. Hara M, Toyoda M, Yaar M, et al. Innervation of melanocytes in human skin. J Exp Med. 1996;184:1385-1395.
62. Brain SD, Williams TJ. Interactions between the tachykinins and calcitonin gene-related peptide lead to the modulation of oedema formation and blood flow in rat skin. Br J Pharmacol. 1989;97:77-82.
63. Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev. 1996:17:533-585.
64. Sung CP, Arleth AJ, Aiyar N, Bhatnagar PK, Lysko PG, Feuerstein G. CGRP stimulates the adhesion of leukocytes to vascular endothelial cells. Peptides. 1992; 13:429-434.
65. Buckley TL, Brain SD, Jose PJ, Williams TJ. The partial inhibition of inflammatory responses induced by capsaicin using the Fab fragment of a selective calcitonin gene-related peptide antiserum in rabbit skin. Neuroscience. 1992;48: 963-968.
66. Hagner S, Haberberger RV, Overkamp D, Hoffmann R, Voigt KH, McGregor GP. Expression and distribution of calcitonin receptor-like receptor in human hairy skin. Peptides. 2002;23:109-116.
67. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998;393:333-339.
68. Nagae T, Mukoyama M, Sugawara A, et al. Rat receptor-activity-modifying proteins (RAMPs) for adrenomedullin/CGRP receptor: cloning and up-regulation in obstructive nephropathy. Biochem Biophys Res Commun. 2000;270:89-93.
69. Hartmeyer M, Scholzen T, Becher E, Bhardwaj RS, Schwarz T, Luger TA. Human dermal microvascular endothelial cells express the melanocortin receptor type 1 and produce increased levels of IL-8 upon stimulation with alpha-melanocyte-stimulating hormone. J Immunol. 1997;159:1930-1937.
70. Bohm M, Luger TA. The pilosebaceous unit is part of the skin immune system. Dermatology. 1998;196:75-79.
71. Grabbe S, Bhardwaj RS, Mahnke K, Simon MM, Schwarz T, Luger TA. alpha-Melanocyte-stimulating hormone induces hapten-specific tolerance in mice. J Immunol. 1996;156:473-478.
72. Kiss M, Wlaschek M, Brenneisen P, et al. Alpha-melanocyte stimulating hormone induces collagenase/matrix metalloproteinase-1 in human dermal fibroblasts. Biol Chem Hoppe Seyler. 1995;376:425-430.
73. Kiss M, Kemeny L, Gyulai R, et al. Effects of the neuropeptides substance P, calcitonin gene-related peptide and alpha-melanocyte-stimulating hormone on the IL-8/IL-8 receptor system in a cultured human keratinocyte cell line and dermal fibroblasts. Inflammation. 1999;23:557-567.
74. Teofoli P, Frezzolini A, Puddu P, De Pita O, Mauviel A, Lotti T. The role of proopiomelanocortin-derived peptides in skin fibroblast and mast cell functions. Ann N Y Acad Sci. 1999;885:268-276.
75. Scholzen TE, Kalden D, Brzoska T, et al. Expression of proopiomelanocortin peptides in human dermal microvascular endothelial cells: evidence for a regulation by ultraviolet light and interleukin-1. J Invest Dermatol. 2000;115:1021-1028.
76. Kalden DH, Scholzen T, Brzoska T, Luger TA. Mechanisms of the anti-inflammatory effects of alpha-MSH: role of transcription factor NF-kappa B and adhesion molecule expression. Ann N Y Acad Sci. 1999;885:254-261.
77. Ichiyama T, Okada K, Campbell IL, Furukawa S, Lipton JM. NF-kappaB activation is inhibited in human pulmonary epithelial cells transfected with alpha-melanocyte-stimulating hormone vector. Peptides. 2000;21:1473-1477.
78. Haycock JW, Wagner M, Morandini R, Ghanem G, Rennie IG, MacNeil S. Alpha-MSH immunomodulation acts via rel/NF-kappa B in cutaneous and ocular melanocytes and in melanoma cells. Ann N Y Acad Sci. 1999;885:396-399.
79. Bohm M, Schulte U, Goez R, Luger TA. Human dermal fibroblasts express melanocortin-1 receptors and respond to a-melanocyte stimulating hormone with increased secretion of IL-8 [abstract]. Arch Dermatol Res. 1998;290:104.
80. Bergman E, Ulfhake B, Fundin BT. Regulation of NGF-family ligands and receptors in adulthood and senescence: correlation to degenerative and regenerative changes in cutaneous innervation. Eur J Neurosci. 2000;12:2694-2706.
81. Marz P, Heese K, Dimitriades-Schmutz B, Rose-John S, Otten U. Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia. 1999;26:191-200.
82. Donnerer J, Schuligoi R, Stein C. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neuroscience. 1992;49:693-698.
83. Fantini F, Magnoni C, Bracci-Laudiero L, Pincelli CT. Nerve growth factor is increased in psoriatic skin [letter]. J Invest Dermatol. 1995;105:854-855.
84. Takafuji S, Bischoff SC, De Weck AL, Dahinden CA. Opposing effects of tumor necrosis factor-alpha and nerve growth factor upon leukotriene C4 production by human eosinophils triggered with N-formyl-methionyl-leucyl-phenylalanine. Eur J Immunol. 1992;22:969-974.
85. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway [see comments]. Nature. 1997;389:816-824.
86. Carr MJ, Kollarik M, Meeker SN, Undem BJ. A role for TRPV1 in bradykinin-induced excitation of vagal airway afferent nerve terminals. J Pharmacol Exp Ther. 2003;304:1275-1279.
87. Rigoni M, Trevisani M, Gazzieri D, et al. Neurogenic responses mediated by vanilloid receptor-1 (TRPV1) are blocked by the high affinity antagonist, iodoresiniferatoxin. Br J Pharmacol. 2003;138:977-985.
88. Dery O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol. 1998;274: C1429-C1452.
89. Vergnolle N. Proteinase-activated receptor-2-activating peptides induce leukocyte rolling, adhesion, and extravasation in vivo. J Immunol. 1999;163:5064-5069.
90. MacFarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev. 2001;53:245-282.
91. Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med. 2000;6: 151-158.
92. de Garavilla L, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. Br J Pharmacol 2001;133:975-987.
93. Emilsson K, Wahlestedt C, Sun MK, Nystedt S, Owman S, Sundelin J. Vascular effects of proteinase-activated receptor 2 agonist peptide. J Vasc Res. 1997; 34:267-272.
94. Molino M, Barnathan ES, Numerof R, et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem. 1997;272:4043-4049.
95. Hou L, Kapas S, Cruchley AT, et al. Immunolocalization of protease-activated receptor-2 in skin: receptor activation stimulates interleukin-8 secretion by keratinocytes in vitro. Immunology. 1998;94:356-362.
96. Hou L, Ravenall S, Macey MG, Harriott P, Kapas S, Howells GL. Protease-activated receptors and their role in IL-6 and NF-IL-6 expression in human gingival fibroblasts. J Periodontal Res. 1998;33:205-211.
97. Brain SD, Williams TJ. Neuropharmacology of peptides in skin. Semin Dermatol. 1988;7:278-283.
98. Brain SD. Sensory neuropeptides: their role in inflammation and wound healing. Immunopharmacology. 1997;37:133-152.
99. Seeliger S, Derian C, Bunnett NW, et al. Proinflammatory role of proteinase-activated receptor-2 during cutaneous inflammation. FASEB J. In press.
100. Steinhoff M, Neisius U, Ikoma T, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci. 2003;23: 6176-6180.
101. Kanke T, MacFarlane SR, Seatter MJ, et al. Proteinase-activated receptor-2-mediated activation of stress-activated protein kinases and inhibitory kappa B kinases in NCTC 2544 keratinocytes. J Biol Chem. 2001;276:31657-31666.
102. Shpacovitch VM, Brzoska T, Buddenkotte J, et al. Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappaB in human dermal microvascular endothelial cells. J Invest Dermatol. 2002;118:380-385.
103. Scholzen T, Steinhoff M, Bonaccorsi P, et al. Neutral endopeptidase terminates substance P-induced inflammation in allergic contact dermatitis. J Immunol. 2001;166:1285-1291.
104. Johnson AR, Coalson JJ, Ashton J, Larumbide M, Erdos EG. Neutral endopeptidase in serum samples from patients with adult respiratory distress syndrome: comparison with angiotensin-converting enzyme. Am Rev Respir Dis. 1985;132:1262-1267.
105. Muns G, Vishwanatha JK, Rubinstein I. Effects of smokeless tobacco on chemically transformed hamster oral keratinocytes: role of angiotensin I-converting enzyme. Carcinogenesis. 1994;15:1325-1327.
106. Olerud JE, Usui ML, Seckin D, et al. Neutral endopeptidase expression and distribution in human skin and wounds. J Invest Dermatol. 1999;112:873-881.
107. Caldwell PR, Seegal BC, Hsu KC, Das M, Soffer RL. Angiotensin-converting enzyme: vascular endothelial localization. Science. 1976;191:1050-1051.
108. Okamoto A, Lovett M, Payan DG, Bunnett NW. Interactions between neutral endopeptidase (EC 3.4.24.11) and the substance P (NK1) receptor expressed in mammalian cells. Biochem J. 1994;299:683-693.
109. Kondepudi A, Johnson A. Cytokines increase neutral endopeptidase activity in lung fibroblasts. Am J Respir Cell Mol Biol. 1993;8:43-49.
110. Borson DB. Roles of neutral endopeptidase in airways. Am J Physiol. 1991; 260:L212-L225.
111. Borson DB, Gruenert DC. Glucocorticoids induce neutral endopeptidase in transformed human tracheal epithelial cells. Am J Physiol. 1991;260:L83-L89.
112. Scholzen TE, Stander S, Riemann H, Brzoska T, Luger TA. Modulation of cutaneous inflammation by angiotensin-converting enzyme. J Immunol. 2003; 170:3866-3873.
113. Scholzen TE, Sunderkotter C, Kalden DH, et al. Alpha-melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression. Endocrinology. 2003;144:360-370.
114. Talme T, Schultzberg M, Sundqvist KG, Marcusson JA. Somatostatin- and factor XIIIa-immunoreactive cells in psoriasis during clobetasol propionate and calciprotriol treatment. Acta Derm Venereol. 1999;79:44-48.
115. Bull HA, Leslie TA, Chopra S, Dowd PM. Expression of nerve growth factor receptors in cutaneous inflammation [see comments]. Br J Dermatol. 1998;139: 776-783.
116. Brain SD. New feelings about the role of sensory nerves in inflammation [news]. Nat Med. 2000;6:134-135.
117. Sabroe RA, Kennedy CT, Archer CB. The effects of topical doxepin on responses to histamine, substance P and prostaglandin E2 in human skin. Br J Dermatol. 1997;137:386-390.
118. Bering B, Moises HW, Muller WE. Muscarinic cholinergic receptors on intact human lymphocytes properties and subclass characterization. Biol Psychiatry. 1987;22:1451-1458.
119. Iyengar B. Modulation of melanocytic activity by acetylcholine. Acta Anat (Basel). 1989;136:139-141.
120. Grando SA, Crosby AM, Zelickson BD, Dahl MV. Agarose gel keratinocyte outgrowth system as a model of skin re-epithelization: requirement of endogenous acetylcholine for outgrowth initiation. J Invest Dermatol. 1993;101:804-810.
121. Grando SA, Horton RM, Pereira EF, et al. A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes. J Invest Dermatol. 1995;105:774-781.
122. Grando SA, Zelickson BD, Kist DA, et al. Keratinocyte muscarinic acetylcholine receptors: immunolocalization and partial characterization. J Invest Dermatol. 1995;104:95-100.
123. Grando SA, Horton RM, Mauro TM, Kist DA, Lee TX, Dahl MV. Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation. J Invest Dermatol. 1996;107:412-418.
124. Zia S, Ndoye A, Nguyen VT, Grando SA. Nicotine enhances expression of the alpha 3, alpha 4, alpha 5, and alpha 7 nicotinic receptors modulating calcium metabolism and regulating adhesion and motility of respiratory epithelial cells. Res Commun Mol Pathol Pharmacol. 1997;97:243-262.
125. Lammerding-Koppel M, Noda S, Blum A, Schaumburg-Lever G, Rassner G, Drews U. Immunohistochemical localization of muscarinic acetylcholine receptors in primary and metastatic malignant melanomas. J Cutan Pathol. 1997;24:137-144.
126. Ndoye A, Buchli R, Greenberg B, et al. Identification and mapping of keratinocyte muscarinic acetylcholine receptor subtypes in human epidermis. J Invest Dermatol. 1998;111:410-416.
127. Schmelz M, Weber S, Kress M. Topical acetyl salicylate and dipyrone attenuate neurogenic protein extravasation in rat skin in vivo. Neurosci Lett. 2000;290: 57-60.
128. Rossi M, Cupisti A, Mariani S, Santoro G, Pentimone F. Endothelium-dependent and endothelium-independent skin vasoreactivity in the elderly. Aging Clin Exp Res. 2002;14:343-346.
129. Arredondo J, Nguyen VT, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA. A receptor-mediated mechanism of nicotine toxicity in oral keratinocytes. Lab Invest. 2001;81:1653-1668.
130. Berghoff M, Kathpal M, Kilo S, Hilz MJ, Freeman R. Vascular and neural mechanisms of ACh-mediated vasodilation in the forearm cutaneous microcirculation. J Appl Physiol. 2002;92:780-788.
131. Kubli S, Boegli Y, Ave AD, et al. Endothelium-dependent vasodilation in the skin microcirculation of patients with septic shock. Shock. 2003;19:274-280.
132. Katz DM, Markey KA, Goldstein M, Black IB. Expression of catecholaminergic characteristics by primary sensory neurons in the normal adult rat in vivo. Proc Natl Acad Sci U S A. 1983;80:3526-3530.
133. Kaji A, Shigematsu H, Fujita K, Maeda T, Watanabe S. Parasympathetic innervation of cutaneous blood vessels by vasoactive intestinal polypeptide-immunoreactive and acetylcholinesterase-positive nerves: histochemical and experimental study on rat lower lip. Neuroscience. 1988;25:353-362.
134. Levine JD, Taiwo YO, Collins SD, Tam JK. Noradrenaline hyperalgesia is mediated through interaction with sympathetic postganglionic neurone terminals rather than activation of primary afferent nociceptors. Nature. 1986;323:158-160.
135. Advenier C, Devillier P. Neurokinins and the skin. Allerg Immunol (Paris). 1993; 25:280-282.
136. Schallreuter KU, Wood JM, Pittelkow MR, Swanson NN. Steinkraus V. Increased in vitro expression of beta 2-adrenoceptors in differentiating lesional keratinocytes of vitiligo patients. Arch Dermatol Res. 1993;285:216-220.
137. Schallreuter KU, Wood JM, Ziegler I, et al. Defective tetrahydrobiopterin and catecholamine bicsynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta 1994;1226:181-192.
138. Oya N, Suzuki Y, Tanemura M, et al. Detection of skin over cysts with spina bifida may be useful not only for preventing neurological damage during labor but also for predicting fetal prognosis. Feral Diagn Ther. 2000;15:156-159.
139. van der Voort R, Keehnen RM, Beulinng EA, Spaargaren M, Pals ST. Regulation of cytokine signaling by B cell antigen receptor and CD40-controlled expression of heparan sulfate proteoglycans. J Exp Med. 2000;192:1115-1124.
140. Ciioca DP, Watanabe N, Isobe M. Apoptosis of peripheral blood lymphocytes is induced by catecholamines. Jpn Heart J. 2000;41:385-398.
141. Chen R, Fairley JA, Zhao ML, et al. Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation. J Immunol. 2002;169:3987-3992.
142. Michikami D, Iwase S, Kamiya A, Qi F, Mano T, Suzumura A. Interrelations of vasoconstrictor sympathetic outflow to skin core temperature during unilateral sole heating in humans. Auton Neurosci. 2001;91:55-61.
143. Ansel JC, Brown JR, Payan DG, Brown MA. Substance P selectively activates TNF-alpha gene expression in murine mast cells. J Immunol. 1993;150:4478-4485.
144. Kramp RA, Genard J, Fourmanoir P, Caron N, Laekeman G, Herman A. Renal hemodynamics and blood flow autoregulation during acute cyclooxygenas inhibition in male rats. Am J Physiol. 1995;268:F468-F479.
145. Columbo M, Horowitz EM, Kagey-Sobotka A, Lichtenstein LM. Substance P activates the release of histamine from human skin mast cells through a pertussis toxin-sensitive and protein kinase C-dependent mechanism. Clin Immunol Immunopathol. 1996;81:68-73.
146. Wiedermann CJ, Auer B, Sitte B, Reinisch N, Schratzberger P, Kahler CM. Induction of endothelial cell differentiation into capillary-like structures by substance P. Eur J Pharmacol. 1996;298:335-358.
147. Quinlan KL, Song IS, Bunnett NW, et al. Neuropeptide regulation of human dermal microvascular endothelial cell ICAM-1 expression and function. Am J Physiol. 1998;275:C1580-C1590.
148. Smith GD, Seckl JR, Harmar AJ. Distribution of neuropeptides in dorsal root ganglia of the rat; substance P, somatostatin and calcitonin gene-related peptide. Neurosci Lett 1993;153:5-8.
149. Regoli D, Rizzi A, Calo G, Nsa Allogho S, Gobeil F. B1 and B2 kinin receptors in various species. Immunopharmacology. 1997;36:143-147.
150. Okabe T, Hide M, Koro O, Yamamoto S. Substance P induces tumor necrosis factor-alpha release from human skin via mitogen-activated protein kinase. Eur J Pharmacol. 2000;398:309-315.
151. Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol. 2002;147:71-79.
152. Burbach GJ, Kim KH, Zivony AS, The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor. J Invest Dermatol. 2001;117:1075-1082.
153. Tainio H. Cytochemical localization of VIP-stimulated adenylate cyclase activity in human sweat glands. Br J Dermatol. 1987;116:323-328.
154. Schulze E, Witt M, Fink T, Hofer A, Funk RH. Immunohistochemical detection of human skin nerve fibers. Acta Histochem. 1997;99:301-309.
155. Hartschuh W, Weihe E, Yanaihara N, Reinecke M. Immunohistochemical localization of vasoactive intestinal polypeptide (VIP) in Merkel cells of various mammals: evidence for a neuromodulator function of the Merkel cell. J Invest Dermatol. 1983;81:361-364
156. Naukkarinen A, Harvima I, Paukkonen K, Aalto ML, Horsmanheimo M. Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. Arch Dermatol Res. 1993;285:341-346.
157. Haegerstrand A, Jonzon B, Dalsgaard CJ, Nilsson J. Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes. Proc Natl Acad Sci U S A. 1989;86:5993-5996.
158. Smith CH, Atkinson B, Morris RW, Hayes N, Foreman JC, Lee TH. Cutaneous responses to vasoactive intestinal polypeptide in chronic idiopathic urticaria. Lancet. 1992;339:91-93.
159. Gonzalez C, Barroso C, Martin C, Gulbenkian S, Estrada C. Neuronal nitric oxide synthase activation by vasoactive intestinal peptide in bovine cerebral arteries. J Cereb Blood Flow Metab. 1997;17:977-984.
160. Eedy DJ, Shaw C, Johnston CF, Buchanan KD. The regional distribution of neuropeptides in human skin as assessed by radioimmunoassay and high-performance liquid chromatography. Clin Exp Dermatol. 1994;19:463-472.
161. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev. 2000;52:269-324.
162. Groneberg DA, Welker P, Fischer TC, et al. Down-regulation of vasoactive intestinal polypeptide receptor expression in atopic dermatitis. J Allergy Clin Immunol. 2003;111:1099-1105.
163. Moller K, Zhang YZ, Hakanson R, et al. Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience. 1993;57:725-732.
164. Warren JB, Cockcroft JR, Larkin SW, et al. Pituitary adenylate cyclase activating polypeptide is a potent vasodilator in humans. J Cardiovasc Pharmacol. 1992; 20:83-87.
165. Delgado M, Munoz-Elias EJ, Kan Y, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. J Biol Chem. 1998;273:31427-31436.
166. Delgado M, Ganea D. VIP and PACAP inhibit activation induced apoptosis in T lymphocytes. Ann N Y Acad Sci. 2000;921:55-67.
167. Schmidt-Choudhury A, Furuta GT, Galli SJ. Schmidt WE, Wershil BK. Mast cells dontribute to PACAP-induced dermal oedema in mice. Regul Pept. 1999;82:65-69.
168. Seebeck J, Kruse ML, Schmidt-Choudhury A, Schmidt WE. Pituitary adenylate cyclase activating polypeptide induces degranulation of rat peritoneal mast cells via high-affinity PACAP receptor-independent activation of GG proteins. Ann N Y Acad Sci. 1998;865:141-146.
169. Vaudry D, Gonzalez BJ, Basille M, Pamantung TF, Fournier A, Vaudry H. PACAP acts as a neurotrophic factor during histogenesis of the rat cerebellar cortex. Ann N Y Acad Sci. 2000;921:293-299
170. Sakashita Y, Kurihara T, Uchida D, Tatsuno I, Yamamoto T. Involvement of PACAP receptor in primary afferent fibre-evoked responses of ventral roots in the neonatal rat spinal cord. Br J Pharmacol. 2001;132:1769-1776.
171. Haegerstrand A, Dalsgaard CJ, Jonzon B, Larsson O, Nilsson J. Calcitonin
172. Jarvikallio A, Harvima IT, Naukkarinen A. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res. 2003;295:2-7.
173. Luger TA, Brzoska T, Scholzen TE, et al. The role of alpha-MSH as a modulator of cutaneous inflammation. Ann N Y Acad Sci. 2000;917:232-238.
174. Grutzkau A, Henz BM, Kirchhof L, Luger T, Artuc M. alpha-Melanocyte stimulating hormone acts as a selective inducer of secretory functions in human mast cells. Biochem Biophys Res Commun. 2000;278:14-19.
175. Catania A, Cutuli M, Garofalo L, et al. The neuropeptide alpha-MSH in host defense. Ann N Y Acad Sci. 2000;917:227-231.
176. Adachi S, Nakano T, Vliagoftis H, Metcalfe DD. Receptor-mediated modulation of murine mast cell function by alpha-melanocyte stimulating hormone. J Immunol. 1999;163:3363-3368.
177. Cone RD, Lu D, Koppula S, et al. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res. 1996; 51:287-317.
178. Brzoska T, Kalden DH, Scholzen T, Luger TA. Molecular basis of the alpha-MSH/IL-1 antagonism. Ann N Y Acad Sci. 1999;885:230-238.
179. Haycock JW, Rowe SJ, Cartledge S, et al. Alpha-melanocyte-stimulating hormone reduces impact of proinflammatory cytokine and peroxide-generated oxidative stress on keratinocyte and melanoma cell lines. J Biol Chem. 2000;275: 15629-15636.
180. Funasaka Y, Chakraborty AK, Yodol J, Ichihashi M. The effect of thioredoxin on the expression of proopiomelanocortin-derived peptides, the melanocortin 1 receptor and cell survival of normal human keratinocytes. J Investig Dermatol Symp Proc. 2001;6:32-37.
181. Curry JL, Pinto W, Nickoloff BJ, Slominski AT. Human keratinocytes express functional alpha-MSH (MC1-R) receptors. In Vitro Cell Dev Biol Anim. 2001; 37:234-236.
182. Virador VM, Muller J, Wu X, et al. Influence of alpha-melanocyte-stimulating hormone and ultraviolet radiation on the transfer of melanosomes to keratinocytes. FASEB J. 2002;16:105-107.
183. Moustafa M, Szabo M, Ghanem GE, et al. Inhibition of tumor necrosis factor-alpha stimulated NFkappaB/p65 in human keratinocytes by alpha-melanocyte stimulating hormone and adrenocorticotropic hormone peptides. J Invest Dermatol. 2002;119:1244-1253.